Lerana

Letrozole, the active ingredient in Lerana, is an aromatase inhibitor presented as a tablet for oral use. It is employed in the treatment of hormone‑receptor positive breast cancer in postmenopausal women, both as adjuvant therapy and for metastatic disease.

GNH USA supplies Lerana as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole acts on estrogen‑dependent breast cancer pathways and is indicated for the following conditions:

- Adjuvant treatment of hormone‑receptor positive breast cancer in postmenopausal women: reduces risk of disease recurrence after surgery. - Metastatic breast cancer in postmenopausal women: helps control tumor progression and prolongs survival. - Hormone‑sensitive breast cancer in postmenopausal patients: lowers circulating estrogen levels to inhibit tumor growth.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient episodes of intense warmth. - Joint and muscle pain: aching or stiffness in limbs. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Osteoporotic fractures: increased risk due to bone density loss. - Deep vein thrombosis: formation of blood clots in deep veins. - Elevated liver enzymes: signs of hepatic stress. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Pulmonary embolism: blockage of lung arteries. - Cardiovascular events: rare heart‑related complications.

Before initiating Letrozole therapy, several safety considerations should be observed.

- Monitor bone health: assess bone mineral density periodically due to estrogen depletion. - Evaluate liver function: check hepatic enzymes before and during treatment. - Assess cardiovascular risk: consider history of thromboembolic disease. - Review concomitant medications: avoid drugs that may interfere with aromatase inhibition. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Letrozole can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Estrogen replacement therapy: antagonizes Letrozole’s intended effect. - Strong CYP2C19 inhibitors (e.g., fluconazole): may raise Letrozole plasma levels. - Tamoxifen: concurrent use reduces therapeutic benefit of both agents.

Moderate Interactions (Monitor Closely): - Warfarin: Letrozole may potentiate anticoagulant effect, increasing INR. - CYP3A4 inducers (e.g., rifampin): may lower Letrozole concentrations. - SSRIs (e.g., fluoxetine): may increase incidence of hot flashes. - Antihypertensives: monitor blood pressure as Letrozole can affect vascular tone.